A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic Cancers
iOnctura
iOnctura
OncoNano Medicine, Inc.
Massive Bio, Inc.
Bio-Path Holdings, Inc.
Celldex Therapeutics
NovalGen Ltd.
Seagen Inc.
Atara Biotherapeutics
Opna Bio LLC
Alexion Pharmaceuticals, Inc.
AbbVie
Pfizer
Progen Pharmaceuticals
Morphotek
Pharmacyclics LLC.
INSYS Therapeutics Inc
Novartis